Objective: To review the literature regarding booster or higher doses of influenza antigen for increasing immunogenicity of inactivated influenza vaccine (IIV) in HIV-infected patients. Data Sources: MEDLINE (1966 to September 2013) was searched using the terms immunize, influenza, vaccine, and HIV or AIDS in combination with two-dose, booster-dose, increased antigen, or high-dose. One trial of booster dosing with standard doses (SDs) of IIV, trivalent (IIV3); 2 trials of booster dosing with intermediate doses (ID) of H1N1 IIV or IIV3; and 1 trial of high-dose (HD) IIV3 were identified. Study Selection and Data Extraction: Trials administering 2-dose, booster-dose, or increased antigen of influenza vaccine to patients with HIV were reviewed. Because adjuvanted IIV is not available and IIV, quadrivalent was recently approved in the United States, studies evaluating these vaccines were excluded. Data Synthesis: HIV-infected individuals are at high risk for influenza-related complications; however, vaccination with SD IIV may not confer optimal protection. It has been postulated that booster or higher doses of influenza antigen may lead to increased immunogenicity. When ID and SD or ID with boosters were evaluated in HIV-infected patients, significant increases in surrogate markers for influenza protection were not achieved. However, HD IIV3 did result in significant increases in seroprotective antibody levels, though ‘clinical’ influenza was not evaluated. Conclusions: Currently, evidence is insufficient to reach conclusions about the efficacy of booster dosing, ID, or HD influenza vaccine in HIV-infected patients. Trials evaluating booster or higher-antigen doses of IIV for ‘clinical’ influenza are necessary before routinely recommending for HIV-infected patients.
Centers for Disease Control and Prevention. Seasonal influenza (flu): people at high risk of developing flu–related complications. http://www.cdc.gov/flu/about/disease/high_risk.htm. Accessed July 30, 2013.
2.
RadwanHMCheesemanSHLaiKKEllisonIR. Influenza in human immunodeficiency virus-infected patients during the 1997-1998 influenza season. Clin Infect Dis. 2000;31:604-606.
3.
NeuzilKMCoffetCSMitchelEFJrGriffenMR. Cardiopulmonary hospitalizations during influenza season in adults and adolescents with advanced HIV infection. J Acquir Immune Defic Syndr. 2003;34:304-307.
4.
LinJCNicholKL. Excess mortality due to pneumonia or influenza during influenza season among persons with acquired immunodeficiency syndrome. Arch Intern Med. 2001;161:441-446.
5.
Centers for Disease Control and Prevention. Seasonal influenza (flu). Summary* recommendations: prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices—(ACIP)—United States, 2013-14. http://www.cdc.gov/flu/professionals/acip/2013-summary-recommendations.htm. Accessed September 10, 2013.
CourchRBKaselJA. Immunity to influenza in man. Annu Rev Microbiol. 1983;37:529-549.
8.
JeffersonTDi PietrantonjCRivettiA. Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2010;(7):CD001269.
9.
TaskerSATreanorJJPaxtonWBWallaceMR. Efficacy of influenza vaccine in HIV-infected persons: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1999;131:430-433.
10.
BrydakLBHryniewiczHJMachalaMHorbanA. Humoral response to influenza vaccination in HIV-infected patients. Clin Drug Investig. 1999;17:441-449.
11.
NelsonKEClementsMLMiottiPCohnSPolkBF. The influence of human immunodeficiency virus (HIV) infection on antibody response to influenza vaccines. Ann Intern Med. 1988;109:383-388.
12.
ZanettiARAmendolaABesanaSBoschiniATanziE. Safety and immunogenicity of influenza vaccination in individuals infected with HIV. Vaccine. 2002;20(suppl 5):B29-B32.
13.
TebasPFrankILewisM. Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. AIDS. 2010;24:2187-2192.
14.
KunisakiKMJanoffEN. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009;9:493-504.
15.
EvisonJFareseSSeitzM. Randomized, double-blind comparative trial of subunit and virosomal influenza vaccines for immunocompromised patients. Clin Infect Dis. 2009;48:1402-1412.
16.
MiottiPGNelsonKEDallabettaGA. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA. 1989;262:779-783.
17.
CooperCThorneAKleinM. Immunogenicity is not improved by increased antigen dose or booster dosing of seasonal influenza vaccine in a randomized trial of HIV adults. PLoS One. 2011;6:1-7.
18.
El SahlyHMDavieCKotloffK. Higher antigen content improves the immune response to 2009 H1N1 influenza vaccine in HIV-infected adults: a randomized clinical trial. J Infect Dis. 2012;205:703-712.
19.
McKittrickNFrankIJacobsonJ. Improved immunogenicity with high-dose seasonal influenza vaccine in HIV-infected persons. Ann Intern Med. 2013;158:19-26.
